Long-term Antibody Persistence of MenHibrix vs ActHIB

Phase 3, open-label trial of haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen in meningococcal disease and Haemophilus influenzae type b infection (Hib) (3 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Anti-Polyribosylribitol Phosphate Antibody Concentrations Greater Than or Equal to 0.15 Microgram Per Milliliter at 5 years, Number of Subjects With Neisseria Meningitidis Serogroup C Antibody Titers Greater Than or Equal to 1:8 at 5 years and 1 more. Started Sep 2006; status: completed.